How to buy Amgen (AMGN) shares in Australia
Learn how to easily invest in Amgen shares.
Amgen Inc is a drug manufacturers - general business with stocks listed in the US. Amgen shares (AMGN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$271.31 – a decrease of 0.42% over the previous week. Here's how to invest if you're based in Australia.
How to buy shares in Amgen
- Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Amgen. Find the share by name or ticker symbol: AMGN. Research its history to confirm it's a solid investment that matches your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Amgen reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$269.35, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Amgen, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Amgen. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.
What's in this guide?
- Amgen key stats
- Compare share trading platforms
- Is Amgen stock a buy or sell?
- Amgen performance over time
- Is Amgen suitable for ethical investing?
- Are Amgen shares over-valued?
- Amgen's financials
- How volatile are Amgen shares?
- Does Amgen pay a dividend?
- Have Amgen shares ever split?
- Other common questions
Amgen stock price (NASDAQ:AMGN)Use our graph to track the performance of AMGN stocks over time.
Have Amgen's shares ever split?
Amgen's shares were split on a 2:1 basis on 22 November 1999. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your Amgen shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Amgen shares which in turn could have impacted Amgen's share price.
Amgen shares at a glance
|52-week range||US$208.3701 - US$286.2096|
|50-day moving average||US$270.1098|
|200-day moving average||US$246.3561|
|Dividend yield||US$8.33 (3.13%)|
|Earnings per share (TTM)||US$14.06|
Amgen price performance over time
|1 week (2023-12-01)||-0.42%|
|1 month (2023-11-08)||-0.71%|
|3 months (2023-09-08)||4.58%|
|6 months (2023-06-08)||22.90%|
|1 year (2022-12-08)||-4.99%|
|2 years (2021-12-08)||27.06%|
|3 years (2020-12-08)||18.51%|
|5 years (2018-12-07)||41.72%|
Compare trading platforms to buy Amgen shares
Is it a good time to buy Amgen stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is Amgen under- or over-valued?
Valuing Amgen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amgen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Amgen's P/E ratio
Amgen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Amgen shares trade at around 19x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Amgen's PEG ratio
Amgen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.2206. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Amgen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Amgen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$13.3 billion (£10.6 billion).
The EBITDA is a measure of a Amgen's overall financial performance and is widely used to measure stock profitability.
Amgen share price volatility
Over the last 12 months, Amgen's shares have ranged in value from as little as US$208.3701 up to US$286.2096. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amgen's is 0.58. This would suggest that Amgen's shares are less volatile than average (for this exchange).
|Revenue TTM||US$26.8 billion|
|Operating margin TTM||38.94%|
|Gross profit TTM||US$19.9 billion|
|Return on assets TTM||7.86%|
|Return on equity TTM||133.8%|
|Market capitalisation||US$145.8 billion|
TTM: trailing 12 months
Amgen share dividends
Dividend payout ratio: 47.25% of net profits
Recently Amgen has paid out, on average, around 47.25% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.13% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Amgen shareholders could enjoy a 3.13% return on their shares, in the form of dividend payments. In Amgen's case, that would currently equate to about $8.33 per share.
While Amgen's payout ratio might seem fairly standard, it's worth remembering that Amgen may be investing much of the rest of its net profits in future growth.
Amgen's most recent dividend payout was on 8 December 2023. The latest dividend was paid out to all shareholders who bought their shares by 16 November 2023 (the "ex-dividend date").
Amgen's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Amgen.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Amgen's total ESG risk score
Total ESG risk: 20.95
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Amgen's overall score of 20.95 (as at 01/01/2019) is pretty good – landing it in it in the 24th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Amgen is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Amgen's environmental score
Environmental score: 1.53/100
Amgen's environmental score of 1.53 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Amgen is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Amgen's social score
Social score: 15.13/100
Amgen's social score of 15.13 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Amgen is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Amgen's governance score
Governance score: 5.8/100
Amgen's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that Amgen is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Amgen's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Amgen scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Amgen has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||20.95|
|Total ESG percentile||23.7|
|Environmental score percentile||3|
|Social score percentile||3|
|Governance score percentile||3|
|Level of controversy||2|
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Stocks similar to Amgen
Frequently asked questions
More guides on Finder
Shein IPO: How to invest in the Shein IPO
What you need to know about investing in Shein from Australia.
Best performing stocks on the ASX in 2023 (Updated weekly)
Looking for the best performing stocks in Australia? We update this list weekly.
Tiger Brokers review for Australians
If you're thinking of trading stocks with Tiger Brokers, check out our review of this online broker's fees, safety and pros and cons first.
How to buy Gol Linhas Aereas Inteligentes SA ADR (GOL) shares in Australia
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
How to buy Caltex Australia shares
Steps to owning and managing Caltex Australia shares from .
A beginner’s guide to Lego investing
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
The cheapest stock brokers in Australia (Dec 2023)
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
What is the money market?
Learn about the money market and everyday consumer money market products.
Is investing in crowdfunding a safe investment?
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
The best trading platforms in Australia
Follow these tips to find the best share trading platform for you.
Ask an Expert